{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:50:22Z","timestamp":1787003422246,"version":"build-2736575974"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,3]],"date-time":"2017-10-03T00:00:00Z","timestamp":1506988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,10,3]],"date-time":"2017-10-03T00:00:00Z","timestamp":1506988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    To secure a polio-free world, the live attenuated oral poliovirus vaccine (OPV) will eventually need to be replaced with inactivated poliovirus vaccines (IPV). However, current IPV delivery is less suitable for campaign use than OPV, and more expensive. We are progressing a microarray patch delivery platform, the Nanopatch, as an easy-to-use device to administer vaccines, including IPV. The Nanopatch contains an ultra-high density array (10,000\/cm\n                    <jats:sup>2<\/jats:sup>\n                    ) of short (~230 \u03bcm) microprojections that delivers dry coated vaccine into the skin. Here, we compare the relative immunogenicity of Nanopatch immunisation versus intramuscular injection in rats, using monovalent and trivalent formulations of IPV. Nanopatch delivery elicits faster antibody response kinetics, with high titres of neutralising antibody after just one (IPV2) or two (IPV1 and IPV3) immunisations, while IM injection requires two (IPV2) or three (IPV1 and IPV3) immunisations to induce similar responses. Seroconversion to each poliovirus type was seen in 100% of rats that received ~1\/40th of a human dose of IPV delivered by Nanopatch, but not in rats given ~1\/8th or ~1\/40th dose by IM injection. Ease of administration coupled with dose reduction observed in this study suggests the Nanopatch could facilitate inexpensive IPV vaccination in campaign settings.\n                  <\/jats:p>","DOI":"10.1038\/s41598-017-13011-0","type":"journal-article","created":{"date-parts":[[2017,9,27]],"date-time":"2017-09-27T11:26:08Z","timestamp":1506511568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["High-density microprojection array delivery to rat skin of low doses of trivalent inactivated poliovirus vaccine elicits potent neutralising antibody responses"],"prefix":"10.1038","volume":"7","author":[{"given":"David A.","family":"Muller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germain J. P.","family":"Fernando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick S.","family":"Owens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiana","family":"Agyei-Yeboah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C. J.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra C. I.","family":"Depelsenaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angus","family":"Forster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Fahey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Weldon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Steven","family":"Oberste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A. F.","family":"Kendall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,3]]},"reference":[{"key":"13011_CR1","doi-asserted-by":"publisher","first-page":"470","DOI":"10.15585\/mmwr.mm6518a4","volume":"65","author":"M Morales","year":"2016","unstructured":"Morales, M., Tangermann, R. H. & Wassilak, S. G. Progress Toward Polio Eradication - Worldwide, 2015\u20132016. MMWR. Morbidity and mortality weekly report \n                           65, 470\u2013473, https:\/\/doi.org\/10.15585\/mmwr.mm6518a4 (2016).","journal-title":"MMWR. Morbidity and mortality weekly report"},{"key":"13011_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-016-0594-6","volume":"14","author":"MJ Toole","year":"2016","unstructured":"Toole, M. J. So close: remaining challenges to eradicating polio. BMC medicine \n                           14, 43, https:\/\/doi.org\/10.1186\/s12916-016-0594-6 (2016).","journal-title":"BMC medicine"},{"key":"13011_CR3","first-page":"1031","volume":"63","author":"OM Kew","year":"2014","unstructured":"Kew, O. M. et al. Possible eradication of wild poliovirus type 3\u2013worldwide, 2012. MMWR. Morbidity and mortality weekly report \n                           63, 1031\u20131033 (2014).","journal-title":"MMWR. Morbidity and mortality weekly report"},{"key":"13011_CR4","unstructured":"WHO. Vaccine-associated paralytic polio (VAPP) and vaccine-derived poliovirus (VDPV, http:\/\/www.who.int\/immunization\/diseases\/poliomyelitis\/endgame_objective2\/oral_polio_vaccine\/VAPPandcVDPVFactSheet-Feb2015.pdf (2015)."},{"key":"13011_CR5","first-page":"527","volume":"64","author":"JE Hagan","year":"2015","unstructured":"Hagan, J. E. et al. Progress toward polio eradication - worldwide, 2014\u20132015. MMWR. Morbidity and mortality weekly report \n                           64, 527\u2013531 (2015).","journal-title":"MMWR. Morbidity and mortality weekly report"},{"key":"13011_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1536-9","volume":"16","author":"RJ Duintjer Tebbens","year":"2016","unstructured":"Duintjer Tebbens, R. J., Hampton, L. M. & Thompson, K. M. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation. BMC infectious diseases \n                           16, 231, https:\/\/doi.org\/10.1186\/s12879-016-1536-9 (2016).","journal-title":"BMC infectious diseases"},{"key":"13011_CR7","unstructured":"UNICEF. Inactivated Polio Vaccine: Supply Update, http:\/\/www.unicef.org\/supply\/files\/IPV_supply_update_May_2015.pdf (2015)."},{"key":"13011_CR8","unstructured":"UNICEF. OPV, http:\/\/www.unicef.org\/supply\/files\/OPV. pdf (2015)."},{"key":"13011_CR9","unstructured":"UNICEF. Inactivated Polio vaccine, http:\/\/www.unicef.org\/supply\/files\/IPV.pdf (2014)."},{"key":"13011_CR10","doi-asserted-by":"publisher","first-page":"4683","DOI":"10.1016\/j.vaccine.2015.01.089","volume":"33","author":"C Edens","year":"2015","unstructured":"Edens, C., Dybdahl-Sissoko, N. C., Weldon, W. C., Oberste, M. S. & Prausnitz, M. R. Inactivated polio vaccination using a microneedle patch is immunogenic in the rhesus macaque. Vaccine \n                           33, 4683\u20134690, https:\/\/doi.org\/10.1016\/j.vaccine.2015.01.089 (2015).","journal-title":"Vaccine"},{"key":"13011_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/srep22094","volume":"6","author":"DA Muller","year":"2016","unstructured":"Muller, D. A. et al. Inactivated poliovirus type 2 vaccine delivered to rat skin via high density microprojection array elicits potent neutralising antibody responses. Scientific reports \n                           6, 22094, https:\/\/doi.org\/10.1038\/srep22094 (2016).","journal-title":"Scientific reports"},{"key":"13011_CR12","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1016\/j.vaccine.2015.02.011","volume":"33","author":"LV Andreasen","year":"2015","unstructured":"Andreasen, L. V., Hansen, L. B., Andersen, P., Agger, E. M. & Dietrich, J. Aluminium hydroxide potentiates a protective Th1 biased immune response against polio virus that allows for dose sparing in mice and rats. Vaccine \n                           33, 1873\u20131879, https:\/\/doi.org\/10.1016\/j.vaccine.2015.02.011 (2015).","journal-title":"Vaccine"},{"key":"13011_CR13","doi-asserted-by":"publisher","first-page":"e110","DOI":"10.1016\/j.ijid.2011.10.002","volume":"16","author":"J Cadorna-Carlos","year":"2012","unstructured":"Cadorna-Carlos, J., Vidor, E. & Bonnet, M. C. Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases \n                           16, e110\u2013116, https:\/\/doi.org\/10.1016\/j.ijid.2011.10.002 (2012).","journal-title":"International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases"},{"key":"13011_CR14","doi-asserted-by":"publisher","first-page":"6816","DOI":"10.1016\/j.vaccine.2015.09.039","volume":"33","author":"A Anand","year":"2015","unstructured":"Anand, A. et al. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial. Vaccine \n                           33, 6816\u20136822, https:\/\/doi.org\/10.1016\/j.vaccine.2015.09.039 (2015).","journal-title":"Vaccine"},{"key":"13011_CR15","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1093\/infdis\/jiu841","volume":"211","author":"SB Troy","year":"2015","unstructured":"Troy, S. B. et al. Comparison of the Immunogenicity of Various Booster Doses of Inactivated Polio Vaccine Delivered Intradermally Versus Intramuscularly to HIV-Infected Adults. J Infect Dis \n                           211, 1969\u20131976, https:\/\/doi.org\/10.1093\/infdis\/jiu841 (2015).","journal-title":"J Infect Dis"},{"key":"13011_CR16","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.vaccine.2011.11.018","volume":"30","author":"KS Nelson","year":"2012","unstructured":"Nelson, K. S., Janssen, J. M., Troy, S. B. & Maldonado, Y. Intradermal fractional dose inactivated polio vaccine: a review of the literature. Vaccine \n                           30, 121\u2013125, https:\/\/doi.org\/10.1016\/j.vaccine.2011.11.018 (2012).","journal-title":"Vaccine"},{"key":"13011_CR17","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.vaccine.2014.11.025","volume":"33","author":"S Resik","year":"2015","unstructured":"Resik, S. et al. Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba. Vaccine \n                           33, 307\u2013313, https:\/\/doi.org\/10.1016\/j.vaccine.2014.11.025 (2015).","journal-title":"Vaccine"},{"key":"13011_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.06.071","author":"S Resik","year":"2015","unstructured":"Resik, S. et al. Needle-free jet injector intradermal delivery of fractional dose inactivated poliovirus vaccine: Association between injection quality and immunogenicity. Vaccine. https:\/\/doi.org\/10.1016\/j.vaccine.2015.06.071 (2015).","journal-title":"Vaccine"},{"key":"13011_CR19","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1086\/651611","volume":"201","author":"S Resik","year":"2010","unstructured":"Resik, S. et al. Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba. J Infect Dis \n                           201, 1344\u20131352, https:\/\/doi.org\/10.1086\/651611 (2010).","journal-title":"J Infect Dis"},{"key":"13011_CR20","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1056\/NEJMoa1202541","volume":"368","author":"S Resik","year":"2013","unstructured":"Resik, S. et al. Priming after a fractional dose of inactivated poliovirus vaccine. N Engl J Med \n                           368, 416\u2013424, https:\/\/doi.org\/10.1056\/NEJMoa1202541 (2013).","journal-title":"N Engl J Med"},{"key":"13011_CR21","doi-asserted-by":"publisher","first-page":"3688","DOI":"10.1016\/j.vaccine.2013.05.104","volume":"31","author":"D Soonawala","year":"2013","unstructured":"Soonawala, D. et al. Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults. Vaccine \n                           31, 3688\u20133694, https:\/\/doi.org\/10.1016\/j.vaccine.2013.05.104 (2013).","journal-title":"Vaccine"},{"key":"13011_CR22","doi-asserted-by":"publisher","first-page":"e534","DOI":"10.1016\/S2214-109X(16)30075-4","volume":"4","author":"E Clarke","year":"2016","unstructured":"Clarke, E. et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles-rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia. The Lancet. Global health \n                           4, e534\u2013547, https:\/\/doi.org\/10.1016\/S2214-109X(16)30075-4 (2016).","journal-title":"The Lancet. Global health"},{"key":"13011_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010266","volume":"5","author":"GJ Fernando","year":"2010","unstructured":"Fernando, G. J. et al. Potent immunity to low doses of influenza vaccine by probabilistic guided micro-targeted skin delivery in a mouse model. PLoS One \n                           5, e10266, https:\/\/doi.org\/10.1371\/journal.pone.0010266 (2010).","journal-title":"PLoS One"},{"key":"13011_CR24","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.jconrel.2011.02.026","volume":"152","author":"X Chen","year":"2011","unstructured":"Chen, X. et al. Improving the reach of vaccines to low-resource regions, with a needle-free vaccine delivery device and long-term thermostabilization. J Control Release \n                           152, 349\u2013355, https:\/\/doi.org\/10.1016\/j.jconrel.2011.02.026 (2011).","journal-title":"J Control Release"},{"key":"13011_CR25","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1016\/j.biomaterials.2010.02.022","volume":"31","author":"ML Crichton","year":"2010","unstructured":"Crichton, M. L. et al. The effect of strain rate on the precision of penetration of short densely-packed microprojection array patches coated with vaccine. Biomaterials \n                           31, 4562\u20134572, https:\/\/doi.org\/10.1016\/j.biomaterials.2010.02.022 (2010).","journal-title":"Biomaterials"},{"key":"13011_CR26","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1038\/jid.2014.174","volume":"134","author":"AC Depelsenaire","year":"2014","unstructured":"Depelsenaire, A. C. et al. Colocalization of cell death with antigen deposition in skin enhances vaccine immunogenicity. The Journal of investigative dermatology \n                           134, 2361\u20132370, https:\/\/doi.org\/10.1038\/jid.2014.174 (2014).","journal-title":"The Journal of investigative dermatology"},{"key":"13011_CR27","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jconrel.2011.10.026","volume":"158","author":"X Chen","year":"2012","unstructured":"Chen, X. et al. Rapid kinetics to peak serum antibodies is achieved following influenza vaccination by dry-coated densely packed microprojections to skin. J Control Release \n                           158, 78\u201384, https:\/\/doi.org\/10.1016\/j.jconrel.2011.10.026 (2012).","journal-title":"J Control Release"},{"key":"13011_CR28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013460","volume":"5","author":"HJ Corbett","year":"2010","unstructured":"Corbett, H. J., Fernando, G. J., Chen, X., Frazer, I. H. & Kendall, M. A. Skin vaccination against cervical cancer associated human papillomavirus with a novel micro-projection array in a mouse model. PLoS One \n                           5, e13460, https:\/\/doi.org\/10.1371\/journal.pone.0013460 (2010).","journal-title":"PLoS One"},{"key":"13011_CR29","doi-asserted-by":"publisher","first-page":"6675","DOI":"10.1016\/j.vaccine.2015.10.081","volume":"33","author":"FE Pearson","year":"2015","unstructured":"Pearson, F. E. et al. Functional anti-polysaccharide IgG titres induced by unadjuvanted pneumococcal-conjugate vaccine when delivered by microprojection-based skin patch. Vaccine \n                           33, 6675\u20136683, https:\/\/doi.org\/10.1016\/j.vaccine.2015.10.081 (2015).","journal-title":"Vaccine"},{"key":"13011_CR30","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1002\/smll.201000331","volume":"6","author":"TW Prow","year":"2010","unstructured":"Prow, T. W. et al. Nanopatch-targeted skin vaccination against West Nile Virus and Chikungunya virus in mice. Small \n                           6, 1776\u20131784, https:\/\/doi.org\/10.1002\/smll.201000331 (2010).","journal-title":"Small"},{"key":"13011_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067888","volume":"8","author":"FE Pearson","year":"2013","unstructured":"Pearson, F. E. et al. Dry-coated live viral vector vaccines delivered by nanopatch microprojections retain long-term thermostability and induce transgene-specific T cell responses in mice. PLoS One \n                           8, e67888, https:\/\/doi.org\/10.1371\/journal.pone.0067888 (2013).","journal-title":"PLoS One"},{"key":"13011_CR32","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.biomaterials.2016.01.015","volume":"84","author":"JW Coffey","year":"2016","unstructured":"Coffey, J. W., Meliga, S. C., Corrie, S. R. & Kendall, M. A. Dynamic application of microprojection arrays to skin induces circulating protein extravasation for enhanced biomarker capture and detection. Biomaterials \n                           84, 130\u2013143, https:\/\/doi.org\/10.1016\/j.biomaterials.2016.01.015 (2016).","journal-title":"Biomaterials"},{"key":"13011_CR33","doi-asserted-by":"publisher","unstructured":"Meliga, S. C. et al. The Hyperelastic and Failure Behaviors of Skin in Relation to the Dynamic Application of Microscopic Penetrators in a Murine Model. Acta biomaterialia, https:\/\/doi.org\/10.1016\/j.actbio.2016.10.021 (2016).","DOI":"10.1016\/j.actbio.2016.10.021"},{"key":"13011_CR34","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1016\/j.vaccine.2015.03.011","volume":"33","author":"H Kraan","year":"2015","unstructured":"Kraan, H. et al. Alternative delivery of a thermostable inactivated polio vaccine. Vaccine \n                           33, 2030\u20132037, https:\/\/doi.org\/10.1016\/j.vaccine.2015.03.011 (2015).","journal-title":"Vaccine"},{"key":"13011_CR35","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jconrel.2016.05.012","volume":"233","author":"SY Tzeng","year":"2016","unstructured":"Tzeng, S. Y. et al. Thermostabilization of inactivated polio vaccine in PLGA-based microspheres for pulsatile release. J Control Release \n                           233, 101\u2013113, https:\/\/doi.org\/10.1016\/j.jconrel.2016.05.012 (2016).","journal-title":"J Control Release"},{"key":"13011_CR36","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/adfm.201000966","volume":"21","author":"X Chen","year":"2011","unstructured":"Chen, X. et al. Site-Selectively Coated, Densely-Packed Microprojection Array Patches for Targeted Delivery of Vaccines to Skin. Adv Funct Mater \n                           21, 464\u2013473, https:\/\/doi.org\/10.1002\/adfm.201000966 (2011).","journal-title":"Adv Funct Mater"},{"key":"13011_CR37","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1039\/c2ra20153d","volume":"2","author":"D Jenkins","year":"2012","unstructured":"Jenkins, D., Corrie, S. R., Flaim, C. & Kendall, M. A. High density and high aspect ratio solid micro-nanoprojection arrays for targeted skin vaccine delivery and specific antibody extraction. RSC Advances \n                           2, 3490\u20133495 (2012).","journal-title":"RSC Advances"},{"key":"13011_CR38","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jconrel.2009.06.029","volume":"139","author":"X Chen","year":"2009","unstructured":"Chen, X. et al. Dry-coated microprojection array patches for targeted delivery of immunotherapeutics to the skin. J Control Release \n                           139, 212\u2013220, https:\/\/doi.org\/10.1016\/j.jconrel.2009.06.029 (2009).","journal-title":"J Control Release"},{"key":"13011_CR39","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/978-1-4939-3292-4_8","volume":"1387","author":"WC Weldon","year":"2016","unstructured":"Weldon, W. C., Oberste, M. S. & Pallansch, M. A. Standardized Methods for Detection of Poliovirus Antibodies. Poliovirus: Methods and Protocols \n                           1387, 145\u2013176, https:\/\/doi.org\/10.1007\/978-1-4939-3292-4_8 (2016).","journal-title":"Poliovirus: Methods and Protocols"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-13011-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-13011-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-13011-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T06:39:16Z","timestamp":1671777556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-13011-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,3]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["13011"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-13011-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,3]]},"assertion":[{"value":"5 May 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.A.F.K. declares competing financial interests as the founder of Vaxxas and is the inventor on several patents currently licensed by Vaxxas. A.F., P.F. and A.C.I.D. are employees of Vaxxas. D.A.M., G.J.P.F. and P.R.Y. are consultants for Vaxxas. Vaxxas is a company developing the Nanopatch for vaccine delivery applications. The remaining authors state no conflict.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"12644"}}